SuperworthQuest Diagnostics Incorporated DGX
Medical - Diagnostics & Research, Healthcare
$229.40
+1.03%
- Market cap
- $25.3B
- PE
- 24.1×
- 10y median 19.1×
- Forward PE
- Price to sales
- 2.2×
- EV/EBIT
- 18.5×
- Revenue, 12 months
- $11.6B
- +10% on a year ago
- Net margin
- 9.2%
- Free cash flow yield
- 5.4%
Quest Diagnostics trades at 24.1× trailing earnings, pricier than 98% of the last ten years. Revenue was $11.6B over the last twelve months, up 10% on a year earlier with a 9% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.3B | $2.4B | $2.4B | $2.5B | $2.6B+15% | $2.7B+12% | $2.8B+15% | $2.8B+13% | $2.8B+7% | $2.9B+9% | $3B+10% | |
| Cost of revenue | $1.6B | $1.6B | $1.6B | $1.7B | $1.8B+14% | $1.8B+12% | $1.8B+14% | $1.9B+11% | $1.9B+8% | $2B+9% | $2B+11% |
| Gross profit | $736M | $771M | $804M | $811M | $858M+17% | $863M+12% | $943M+17% | $949M+17% | $910M+6% | $942M+9% | $1B+9% |
| SG&A | $407M | $440M | $416M | $448M | $466M+15% | $476M+8% | $486M+17% | $501M+12% | $504M+8% | $504M+6% | $529M+9% |
| $267M | $300M | $355M | $330M | $361M+35% | $346M+15% | $438M+23% | $386M+17% | $386M+7% | $399M+15% | $459M+5% | |
| Interest expense | $46M | $49M | $47M | $58M | $72M+57% | $72M+47% | $69M+47% | $69M+19% | $67M−7% | $63M−13% | $63M−9% |
| Pre-tax income | $237M | $266M | $314M | $296M | $299M+26% | $276M+4% | $384M+22% | $328M+11% | $330M+10% | $334M+21% | $412M+7% |
| $40M | $66M | $74M | $65M | $68M+70% | $59M−11% | $97M+31% | $77M+19% | $81M+19% | $74M+25% | $88M−9% | |
| Net income | $192M | $194M | $229M | $226M | $222M+16% | $220M+13% | $282M+23% | $245M+8% | $245M+10% | $252M+15% | $320M+14% |
| $1.70 | $1.72 | $2.03 | $1.99 | $1.95+15% | $1.94+13% | $2.47+22% | $2.16+9% | $2.18+12% | $2.24+16% | $2.84+15% | |
| 113M | 112M | 112M | 113M | 113M+0% | 113M+1% | 113M+1% | 113M+0% | 112M−1% | 112M−1% | 112M−1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times Quest Diagnostics's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DGXQuest Diagnostics Incorporated | $25.3B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| LHLabcorp Holdings Inc. | $25.5B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| MTDMettler-Toledo International Inc. | $30.6B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| ILMNIllumina, Inc. | $39.5B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IDXXIDEXX Laboratories, Inc. | $40.4B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| WATWaters Corporation | $42B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| IQVIQVIA Holdings Inc. | $42.2B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| AAgilent Technologies, Inc. | $47.2B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| DHRDanaher Corporation | $151.8B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| TMOThermo Fisher Scientific Inc. | $239.9B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| Peer median | $42B | 35.6× | 35.0× | 6.5× | +7% | 15.9% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .